2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.08D.02 Adjuvant Treatment Options after Neoadjuvant Chemotherapy Combined with Immunotherapy and Surgery in Patients with Non-Small Cell Lung Cancer

EP.08D.02 Adjuvant Treatment Options after Neoadjuvant Chemotherapy Combined with Immunotherapy and Surgery in Patients with Non-Small Cell Lung Cancer

Back to course

Pdf Summary

The study presented by Yintao Li at the Shandong Cancer Hospital and Institute explored the effectiveness of adjuvant treatment options following neoadjuvant immunotherapy combined with chemotherapy (NICT) and surgery in patients with non-small cell lung cancer (NSCLC). Although the role of NICT is recognized, the optimal postoperative adjuvant therapy remains controversial. This research aimed to determine whether adding immunotherapy to chemotherapy as adjuvant therapy improves outcomes.<br /><br />Researchers retrospectively analyzed data from NSCLC patients treated with NICT and surgery between January 2019 and December 2022. Patients were divided into two groups: those receiving only chemotherapy (Chemo group) and those receiving chemotherapy combined with immunotherapy (ImmunoChemo group). The analysis focused on disease-free survival (DFS) and overall survival (OS) of these two groups.<br /><br />The study included 209 patients and found that the ImmunoChemo group showed a significant advantage in both DFS and OS compared to the Chemo group. Specifically, 1-year DFS was 94.4% in the ImmunoChemo group versus 70.8% in the Chemo group, and 3-year OS was 78.9% versus 64.6%. Among patients who achieved a pathological complete remission (pCR) post-surgery, there was no substantial difference in DFS and OS between the groups. However, for those with pathological non-complete remission (Non-pCR), the ImmunoChemo group demonstrated significantly better outcomes.<br /><br />In conclusion, the study suggests that adding immunotherapy to chemotherapy following NICT and surgery provides a significant survival advantage for NSCLC patients, particularly those who do not achieve a pCR. This finding underscores the potential benefit of incorporating immunotherapy in adjuvant treatments to improve patient outcomes.

Asset Subtitle

Junfeng Zhao

Meta Tag

Speaker Junfeng Zhao

Topic Local-Regional Non-small Cell Lung Cancer

Keywords

NSCLC

adjuvant therapy

immunotherapy

chemotherapy

neoadjuvant treatment

disease-free survival

overall survival

pathological complete remission

Shandong Cancer Hospital

Yintao Li